心力衰竭患者脑钠肽、C反应蛋白与心功能的关系被引量：13

导出

摘要目的:探讨心力衰竭患者脑钠肽、C反应蛋白(CRP)、心功能分级与心功能之间的相互关系。方法:将51例心力衰竭患者与15例健康对照者抽血测定血浆B型脑钠肽(BNP)及血清CRP浓度,同时用彩色多普勒超声心动图仪测定左室射血分数(LVEF)、左室舒张末期内径(LVDD),心力衰竭组根据美国纽约心脏病(NYHA)心功能分级标准分为Ⅱ、Ⅲ、Ⅳ级组。结果:心力衰竭各组BNP、CRP、LVDD均较对照组显著增高,而LVEF明显降低(P值均小于0.01);BNP和CRP随着心功能分级的增加而显著增加(P<0.05);线性回归分析示BNP与LVEF(r=-0.897,P<0.01)、LVDD(r=0.740,P<0.01)、心功能分级(r=0.793,P<0.01)均有显著的相关性,而CRP只与心功能分级(r=0.397,P=0.02)相关,与LVEF(r=0.197,P=0.083)、LVDD(r=0.389,P=0.065)无关。结论:心力衰竭患者血浆BNP和血清CRP随着心力衰竭程度的加重而相应升高,BNP与左心功能状态有良好的相关性,而CRP则没有这种相关性。

作者卢敏张梦玺曹军香

机构地区广东省东莞市黄江医院内二科中南大学湘雅三医院

出处《实用医学杂志》 CAS 2007年第5期658-660,共3页 The Journal of Practical Medicine

关键词心力衰竭充血性脑钠肽 C反应蛋白心功能

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1Shan S J, Marcus G M, Gerber I L, et al. High-sensitivity Creactive protein and parameters of left ventricular dysfunction [J]. J Card Fail ,2006,12( 1 ) :61-65.
2Maisel A, Krishnaswamy P, Nowak R, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure [J]. N Engl J Med, 2002,347(3) : 161-167.
3Yin W H, Chen J W, Jen H L, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failue [J]. Am Heart J, 2004,147(5) :931-938.
4贺桦,许顶立,刘彦波,屠燕.慢性心力衰竭患者血清CRP水平的变化及临床意义[J].中国分子心脏病学杂志,2004,4(2):114-117. 被引量：13
5乔延国,井茹芳,李卉,黄志刚,梁立武,韩盈.心衰康复治疗中脑利钠肽的恢复与心功能改善的关系[J].实用医学杂志,2006,22(11):1253-1254. 被引量：5
6de-Lemos J A, McGuire D K, Drazner M H. B-type natriuretic peptide in cardiovascular disease [J]. Lancet,2003,362 (9380):316-322.
7Berdague P, Caffin P Y, Barazer I, et al. Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients [J]. Am Heart J, 2006,151 (3) :690-698.

二级参考文献18

1李志斌,李志超,闫志强,宋景春,赵彭涛.心房钠尿肽对脂多糖引起肺微血管内皮细胞损伤的治疗作用[J].第四军医大学学报,2005,26(4):289-292. 被引量：13
2[2]Ridker PM,Glynn RJ,Hennekens CH.C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.Circulation,1998,97:2007～2011.
3[3]Ferranti SD,Rifai N.C-reactive protein and cardiovascular disease:a review of risk prediction and intervention.Clin Chim Acta.2002,317;1～15.
4[4]Hunt SA,Baker DW,Chim MH,et al.ACC/AHA Guidelines for the Evaluation and Management of Chronic heart failure in the Adult..Executive Summary A Report of the American College Of Cardiology/ American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 Guidelines for the Evaluations and Management of Heart Failure).Circulation,2001,104(24):2996～3007.
5[5]Maisel A.B-Type Natriuretic Peptide Levels:Diagnostic and Prognostic in Congestive Heart Failure:What's Next? Circulation,2002 105:2328～2331.
6[6]Berger R,Huelsmann M,Samson S,et al.B-type natriuretic peptide predicts sudden death in patients with chronic heart failure-A selection mode for ICD implantation.J Am Coll Cardiol,2002,39(suppl B):193B.
7[8]Arici M,Walls J.End-stage renal disease,antheroscerlosis and cardiovascular mortality:Is C-reaactive protein in the miss link?.Kidney Int,2001,59:407.
8[9]Werdan K.The activated immune system in congestive heart failure.From dropsy to the cytokine paradigm.J Intern Med 1998,243:87～92.
9[10]Ferrari R,Bachetti T,Confortini R,et al.Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure.Circulation 1995,92:1479～1486.
10[11]MacGowan GA,Mann DL,Kormos RL,Feldman AM,Murali S.Circulating interleukin-6 in severe heart failure.Am J Cardiol 1997;79:1128～31.